Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Purpose: Neoadjuvant chemotherapy (NACT) with dual HER2 targeting improved pCR rates (ypT0ypN0) compared with herceptin plus chemotherapy in the TRYPHAENA and NeoSphere registration trials. Pertuzumab-containing regimens FEC-THP and TCHP were adopted at KOC following NICE approval (December 2016).
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Purpose: There is no official national prospective data collection on the number of people living with metastatic breast cancer (MBC) in the UK; the scale of the problem is unknown. Outcome data from conventional first line metastatic treatments in UK tertiary cancer centres are lacking.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
